Subtopic Deep Dive
Lafora Disease Genetics
Research Guide
What is Lafora Disease Genetics?
Lafora Disease Genetics studies mutations in EPM2A and NHLRC1 genes that cause Lafora disease, a fatal progressive myoclonus epilepsy characterized by polyglucosan inclusions and neuronal loss.
Mutations in EPM2A, encoding laforin phosphatase, were first identified by Minassian et al. (1998, 486 citations) and Serratosa (1999, 226 citations). NHLRC1 mutations, encoding malin E3 ligase, were discovered by Chan et al. (2003, 323 citations). Over 20 papers detail genotype-phenotype correlations and mouse models like Ganesh (2002, 241 citations).
Why It Matters
Lafora disease genetics enables precision diagnostics for this rare glycogen storage disease, identifying EPM2A/NHLRC1 mutations in patients with myoclonus epilepsy (Minassian et al., 1998; Chan et al., 2003). Insights into laforin-malin regulation of glycogen prevent polyglucosan accumulation, informing gene therapies (Gentry et al., 2005, 236 citations). Ketogenic diets mitigate symptoms in epilepsy models (Kossoff et al., 2008, 594 citations), advancing treatments for progressive myoclonus epilepsies.
Key Research Challenges
Genotype-Phenotype Correlation
Varied mutations in EPM2A and NHLRC1 yield diverse onset ages and severity, complicating predictions (Ganesh, 2002). Functional impacts on laforin-malin complex differ across patients. Over 100 mutations identified, but correlations remain incomplete.
Lafora Body Formation Mechanism
Neuronal glycogen hyperphosphorylation leads to polyglucosan inclusions despite suppressed synthesis (Vílchez et al., 2007, 363 citations). Laforin-malin ubiquitinates proteins to prevent this, but failure mechanisms unclear (Gentry et al., 2005). Animal models show neurodegeneration but not full human pathology.
Therapeutic Translation from Models
Epm2a knockout mice develop Lafora bodies and myoclonus (Ganesh, 2002), but therapies like gene replacement untested in humans. Ketogenic diets help epilepsy (Kossoff et al., 2008) yet fail to clear inclusions. Clinical trials limited by rarity.
Essential Papers
Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group
Eric H. Kossoff, Beth Zupec‐Kania, Stéphane Auvin et al. · 2018 · Epilepsia Open · 683 citations
Summary Ketogenic dietary therapies ( KDTs ) are established, effective nonpharmacologic treatments for intractable childhood epilepsy. For many years KDTs were implemented differently throughout t...
Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group
Eric H. Kossoff, Beth Zupec‐Kania, Per Åmark et al. · 2008 · Epilepsia · 594 citations
Summary The ketogenic diet (KD) is an established, effective nonpharmacologic treatment for intractable childhood epilepsy. The KD is provided differently throughout the world, with occasionally si...
Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy
Berge A. Minassian, Jeffrey R. Lee, Jo-Anne Herbrick et al. · 1998 · Nature Genetics · 486 citations
Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy
David Vı́lchez, Susana R�os, Daniel Cifuentes et al. · 2007 · Nature Neuroscience · 363 citations
Mutations in NHLRC1 cause progressive myoclonus epilepsy
Elayne M. Chan, Edwin J. Young, Leonarda Ianzano et al. · 2003 · Nature Genetics · 323 citations
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice
Subramaniam Ganesh · 2002 · Human Molecular Genetics · 241 citations
Mutations in the EPM2A gene encoding a dual-specificity phosphatase (laforin) cause Lafora disease (LD), a progressive and invariably fatal epilepsy with periodic acid-Schiff-positive (PAS+) cytopl...
Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin
Matthew S. Gentry, Carolyn A. Worby, Jack E. Dixon · 2005 · Proceedings of the National Academy of Sciences · 236 citations
Lafora disease (LD) is a fatal form of progressive myoclonus epilepsy caused by recessive mutations in either a gene encoding a dual-specificity phosphatase, known as laforin, or a recently identif...
Reading Guide
Foundational Papers
Read Minassian et al. (1998, 486 citations) first for EPM2A discovery, then Chan et al. (2003, 323 citations) for NHLRC1, Ganesh (2002, 241 citations) for mouse models establishing core genetics.
Recent Advances
Study Gentry et al. (2005, 236 citations) for malin ubiquitin ligase function; Vílchez et al. (2007, 363 citations) for glycogen suppression failure; Kossoff et al. (2008, 594 citations) for ketogenic therapy protocols.
Core Methods
Gene sequencing and linkage analysis identify mutations (Minassian 1998, Serratosa 1999); Epm2a/Nhlrc1 knockouts model inclusions (Ganesh 2002); co-immunoprecipitation shows laforin-malin complex (Gentry 2005).
How PapersFlow Helps You Research Lafora Disease Genetics
Discover & Search
Research Agent uses searchPapers('Lafora disease EPM2A NHLRC1 mutations') to find Minassian et al. (1998), then citationGraph reveals 486 downstream papers on laforin phosphatase. exaSearch('genotype-phenotype Lafora') uncovers rare variants; findSimilarPapers on Chan et al. (2003) surfaces 323 NHLRC1 studies.
Analyze & Verify
Analysis Agent runs readPaperContent on Ganesh (2002) to extract Epm2a mouse model data, then runPythonAnalysis parses mutation frequencies with pandas for statistical correlations. verifyResponse (CoVe) checks claims against Vílchez et al. (2007); GRADE grading scores evidence strength for laforin-malin pathway (high confidence from 236+ citations).
Synthesize & Write
Synthesis Agent detects gaps in therapeutic models from Gentry et al. (2005), flags contradictions in glycogen regulation across papers. Writing Agent uses latexEditText for genotype tables, latexSyncCitations integrates 10 key papers, latexCompile generates review PDF; exportMermaid diagrams laforin-malin ubiquitin pathway.
Use Cases
"Analyze EPM2A mutation frequencies in Lafora patients from 1998-2010 papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas counts mutations from Ganesh 2002, Minassian 1998 abstracts) → CSV export of allele stats with p-values.
"Write LaTeX review on NHLRC1-malin function with citations and pathway figure"
Research Agent → citationGraph(Chan 2003) → Synthesis → gap detection → Writing Agent → latexEditText + latexSyncCitations(Gentry 2005) + exportMermaid(ubiquitin pathway) → latexCompile → PDF.
"Find GitHub repos with Lafora disease mouse model code"
Research Agent → paperExtractUrls(Ganesh 2002) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for Epm2a knockouts.
Automated Workflows
Deep Research workflow scans 50+ Lafora genetics papers via searchPapers('EPM2A NHLRC1'), structures report on mutations with GRADE scores. DeepScan applies 7-step CoVe to verify laforin-malin claims from Gentry (2005). Theorizer generates hypotheses on polyglucosan clearance from Vílchez (2007) + mouse data.
Frequently Asked Questions
What defines Lafora Disease Genetics?
Study of EPM2A (laforin) and NHLRC1 (malin) mutations causing fatal myoclonus epilepsy with Lafora bodies (Minassian et al., 1998; Chan et al., 2003).
What methods identify Lafora mutations?
Gene sequencing detects EPM2A tyrosine phosphatase mutations (Serratosa, 1999); linkage analysis mapped NHLRC1 (Chan et al., 2003). Mouse knockouts model pathology (Ganesh, 2002).
What are key papers?
Minassian et al. (1998, 486 citations) discovered EPM2A; Chan et al. (2003, 323 citations) found NHLRC1; Gentry et al. (2005, 236 citations) defined malin-laforin interaction.
What open problems exist?
Unclear why glycogen accumulates despite neuronal suppression (Vílchez et al., 2007); genotype-phenotype links weak; no approved therapies despite mouse models (Ganesh, 2002).
Research Glycogen Storage Diseases and Myoclonus with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lafora Disease Genetics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers